A late-stage trial found Cubist Pharmaceuticals' antibiotic candidate, a combination of ceftolozane and tazobactam, was noninferior to meropenem in treating patients with abdominal infections. Results of this trial mirrored the outcome of another late-stage study released last month that showed Cubist's antibiotic was effective in treating urinary tract infection. Based on these findings, Cubist plans to submit the drug for U.S. and European review as a treatment for abdominal and urinary tract infections next year.

Related Summaries